Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

Inclusion criteria * Confirmed adenocarcinoma of the colon or rectum in patients with metastatic disease * One prior chemotherapy regimen with irinotecan and 5FU * Evidence of progressive disease within 6 months after last dose of irinotecan * WHO Performance Status of 0, 1, or 2 * Measurable tumors * Adequate hematologic status, liver and kidney function * Life expectancy greater than 12 weeks * Written informed consent obtained Exclusion criteria * History or presence of central nervous system disease * Patients with a history of another primary cancer within 5 years * Prior chemotherapy within 3 weeks before entry to study * Major surgery within 4 weeks or minor surgery within 2 weeks before entry to study * Investigational drugs within 4 weeks before entry to study * Prior therapy with oxaliplatin * Peripheral neuropathy with functional impairment * Female patients who are pregnant or breast feeding * Any severe or uncontrolled medical condition which could prevent participation in study * Chronic kidney disease * Acute or chronic liver disease * Patients taking Coumadin